source
- CG Oncology reports 68% drop in bladder cancer recurrence in phase 3 trial of cretostimogeneCG Oncology announced results from a phase 3 study of its oncolytic virus immunotherapy, cretostimogene, in patients with non-muscle invasive bladder cancer after surgery. The trial, involving 367…
- Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug DiscoveriesScientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…